1. Academic Validation
  2. Fragment-Based Discovery of Drug-like LRH-1 Agonists

Fragment-Based Discovery of Drug-like LRH-1 Agonists

  • ACS Med Chem Lett. 2025 Mar 20;16(4):575-582. doi: 10.1021/acsmedchemlett.4c00604.
Alisa Lang 1 Niklas Ildefeld 1 Felix F Lillich 2 Astrid Kaiser 1 Romy Busch 3 Julian A Marschner 3 Ewgenij Proschak 1 Jan Heering 2 Manfred Schubert-Zsilavecz 1 Daniel Merk 1 3
Affiliations

Affiliations

  • 1 Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.
  • 2 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60596 Frankfurt, Germany.
  • 3 Department of Pharmacy, Ludwig-Maximilians-Universität (LMU) München, 81377 Munich, Germany.
Abstract

The phospholipid sensing transcription factor liver receptor homologue 1 (LRH-1) participates in the transcriptional regulation of metabolic balance and inflammation in liver, pancreas, and Other tissues. It is an emerging target for metabolic dysfunction, fatty liver disease, and Cancer, but LRH-1 modulators are rare and lack drug-like properties. We discovered new LRH-1 ligands with improved physicochemical features in a fragment-based approach and optimized a venlafaxine-related lead for LRH-1 activation. Despite a strict structure-activity relationship, systematic structural variation resulted in a new LRH-1 agonist scaffold with strong activation efficacy, validated direct and cellular target engagement, and anti-inflammatory and ER-stress-resolving properties in functional cellular settings.

Figures
Products